InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

November 16, 2022

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

November 11, 2022

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

November 10, 2022

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

October 26, 2022

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

September 23, 2022

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

September 13, 2022

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

September 9, 2022

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

September 8, 2022

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

August 23, 2022

InMed Announces Changes to its Board of Directors

August 9, 2022

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

July 25, 2022

InMed Announces Appointment of Chief Operating Officer

July 18, 2022

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

July 12, 2022

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

June 14, 2022

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

June 9, 2022

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 6, 2022

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 2, 2022

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

May 13, 2022

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

May 2, 2022

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

April 28, 2022

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

InMed Announces Changes to its Board of Directors

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

InMed Announces Appointment of Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals